Sigilon Therapeutics (NASDAQ:SGTX) Trading Down 0.6%
Sigilon Therapeutics (NASDAQ:SGTX) Trading Down 0.6%
Sigilon Therapeutics, Inc. (NASDAQ:SGTX – Get Rating) shares were down 0.6% on Tuesday . The stock traded as low as $0.93 and last traded at $0.93. Approximately 28,516 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 429,872 shares. The stock had previously closed at $0.94.
西吉隆治療, 公司. (納斯達克:SGTX — 獲取評級) 股份下降 0.6% 在星期二.該股票的交易價格低至 0.93 美元，最後交易價格為 0.93 美元。在日中交易期間交易了約 28,516 股，較每日平均成交量 429,872 股下跌 93%。該股票之前已收盤 0.94 美元。
Wall Street Analyst Weigh In
華爾街分析師稱重
Separately, Canaccord Genuity Group started coverage on Sigilon Therapeutics in a report on Wednesday, January 18th. They issued a "buy" rating and a $6.00 price objective for the company.
另外, 坎雅克真正集團開始覆蓋西吉隆治療在週三的報告, 1 月 18 日.他們為公司發布了「買入」評級和 6.00 美元的價格目標。
Sigilon Therapeutics Stock Down 0.6 %
西吉隆治療藥物庫存下降 0.6%
The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.31. The firm has a market cap of $30.20 million, a PE ratio of -0.69 and a beta of 0.86. The stock has a fifty day simple moving average of $0.87 and a two-hundred day simple moving average of $0.60.
該公司的流動比率為 2.40，快速比率為 2.40，債務與權益比率為 0.31。該公司的市值為 32000 萬美元，私募股權比率為 -0.69，貝塔值為 0.86。該股有 50 天的簡單移動平均線 0.87 美元和 200 天的簡單移動平均線 0.60 美元。
Institutional Inflows and Outflows
機構流入和流出
A number of hedge funds have recently added to or reduced their stakes in SGTX. Millennium Management LLC purchased a new position in Sigilon Therapeutics during the 2nd quarter valued at about $256,000. Renaissance Technologies LLC grew its holdings in Sigilon Therapeutics by 131.8% during the 1st quarter. Renaissance Technologies LLC now owns 275,600 shares of the company's stock valued at $405,000 after buying an additional 156,689 shares in the last quarter. State Street Corp grew its holdings in Sigilon Therapeutics by 26.7% during the 1st quarter. State Street Corp now owns 330,471 shares of the company's stock valued at $486,000 after buying an additional 69,662 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Sigilon Therapeutics by 22.3% during the 3rd quarter. Vanguard Group Inc. now owns 300,912 shares of the company's stock valued at $152,000 after buying an additional 54,770 shares in the last quarter. Hedge funds and other institutional investors own 52.20% of the company's stock.
一些對沖基金最近增加或減少了他們在 SGTX 的股份。千禧管理有限責任公司在第二季度購買了新的位置，價值約為 256,000 美元。文藝復興技術有限責任公司在西吉隆治療藥物的持有量增長 131.8% 在第一季度.文藝復興科技有限責任公司現在擁有該公司股票的 275,600 股價值為 405,000 美元，在上一個季度額外購買 156,689 股之後。州街公司在第一季度增長了其在西吉隆治療學的持有 26.7%.州街公司現在擁有該公司股票 330,471 股，價值為 486,000 美元，在上一季度額外購買 69,662 股股票後。最後, 先鋒集團公司. 在第三季度增長了其在西吉隆治療的持有 22.3%.領航集團股份有限公司在上一季度額外購入 54,770 股股份後，擁有該公司股票價值 152,000 美元的 300,912 股。對沖基金和其他機構投資者擁有公司股票的 52.20％。
About Sigilon Therapeutics
關於西吉隆治療
(Get Rating)
(取得評分)
Sigilon Therapeutics, Inc, a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes.
Sigilon 治療, Inc 是一家臨床階段生物技術公司，為慢性疾病患者開發功能療法。其主要候選產品為 SIG-001，目前正在進行 I/II 期臨床試驗，以防止中度至重度血友病患者出血發作的 SIG-005。該公司還開發，用於治療 1 型粘多糖病的非神經學表現；SIG-007 提供持續和長期釋放功能酶，足以產生臨床益處和緩解下游治療的 Fabry ISlet 細胞的進展；提供功能酶的持續和長期釋放，以產生臨床益處和緩解法布里病細胞的下游治療方面的進展；提供功能酶的持續和長期釋放。1 型糖尿病。SIG-002
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Sigilon Therapeutics (SGTX)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
- 獲取有關西吉隆治療學（SGTX）的研究報告的免費副本
- 盈利井噴後，Ciena 股票是一個購買機會嗎？
- 這就是為什麼維京療法在肥胖症藥物數據上漲了 50％ 以上的原因
- Meta 突破了基礎，看起來再次成長股
- 底部是在麥考密克 & 公司
- 沃爾格林靴子聯盟：藍籌，高收益周轉故事
Receive News & Ratings for Sigilon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigilon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收西吉隆治療學的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Sigilon 治療和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。